Works by Lesokhin, A.

Results: 61
    1

    Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01321-w
    By:
    • Einarsdottir, Sigrun;
    • Lobaugh, Stephanie;
    • Luan, Danny;
    • Gomez-Llobell, Marina;
    • Subramanian, Padmapriya;
    • Devlin, Sean;
    • Chung, David;
    • Dahi, Parastoo B.;
    • Falchi, Lorenzo;
    • Giralt, Sergio;
    • Landau, Heather;
    • Lesokhin, Alexander M.;
    • Lin, Richard;
    • Lue, Jennifer;
    • Mailankody, Sham;
    • Palomba, M. Lia;
    • Park, Jae H.;
    • Salles, Gilles;
    • Scordo, Michael;
    • Escribano-Serrat, Silvia
    Publication type:
    Article
    2
    3

    Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach.

    Published in:
    American Journal of Hematology, 2023, v. 98, n. 3, p. 421, doi. 10.1002/ajh.26801
    By:
    • Pianko, Matthew J.;
    • Tiutan, Timothy;
    • Derkach, Andriy;
    • Flynn, Jessica;
    • Salvatore, Steven P.;
    • Jaffer‐Sathick, Insara;
    • Rossi, Adriana C.;
    • Lahoud, Oscar;
    • Hultcrantz, Malin;
    • Shah, Urvi A.;
    • Maclachlan, Kylee;
    • Chung, David J.;
    • Shah, Gunjan L.;
    • Landau, Heather J.;
    • Korde, Neha;
    • Mailankody, Sham;
    • Lesokhin, Alexander M.;
    • Tan, Carlyn;
    • Scordo, Michael;
    • Jaimes, Edgar A.
    Publication type:
    Article
    4

    Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi‐institutional experience.

    Published in:
    American Journal of Hematology, 2022, v. 97, n. 7, p. E276, doi. 10.1002/ajh.26580
    By:
    • Mohan, Meera;
    • Becnel, Melody Renee;
    • Shah, Urvi A.;
    • Dong, Huaying;
    • Gundarlapalli, Sravani;
    • Peterson, Timothy;
    • Orozco, Jennifer S.;
    • Horowitz, Sandra;
    • Chhabra, Saurabh;
    • Dhakal, Binod;
    • Thanendrarajan, Sharmilan;
    • Radhakrishnan, Sabarinath Venniyil;
    • Al Hadidi, Samer;
    • Tan, Carlyn;
    • Mailankody, Sham;
    • Hultcrantz, Malin;
    • Korde, Neha;
    • Hassoun, Hani;
    • Lesokhin, Alexander M.;
    • Thomas, Sheeba K.
    Publication type:
    Article
    5

    Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m<sup>2</sup>) in combination with lenalidomide and dexamethasone.

    Published in:
    American Journal of Hematology, 2021, v. 96, n. 6, p. E193, doi. 10.1002/ajh.26150
    By:
    • Korde, Neha;
    • Mastey, Donna;
    • Tavitian, Elizabet;
    • Mailankody, Sham;
    • Lesokhin, Alexander;
    • Hassoun, Hani;
    • Smith, Eric L.;
    • Lendvai, Nikoletta;
    • Hultcrantz, Malin;
    • Shah, Urvi;
    • Tan, Carlyn;
    • Lu, Sydney;
    • Diamond, Benjamin;
    • Salcedo, Meghan;
    • Werner, Kelly;
    • Chung, David J.;
    • Scordo, Michael;
    • Shah, Gunjan L.;
    • Lahoud, Oscar;
    • Landau, Heather
    Publication type:
    Article
    6

    Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma.

    Published in:
    Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01048-0
    By:
    • Costa, Bruno Almeida;
    • Flynn, Jessica;
    • Nishimura, Noriko;
    • Devlin, Sean M.;
    • Farzana, Tasmin;
    • Rajeeve, Sridevi;
    • Chung, David J.;
    • Landau, Heather J.;
    • Lahoud, Oscar B.;
    • Scordo, Michael;
    • Shah, Gunjan L.;
    • Hassoun, Hani;
    • Maclachlan, Kylee;
    • Hultcrantz, Malin;
    • Korde, Neha;
    • Lesokhin, Alexander M.;
    • Shah, Urvi A.;
    • Tan, Carlyn R.;
    • Giralt, Sergio A.;
    • Usmani, Saad Z.
    Publication type:
    Article
    7
    8

    Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00882-y
    By:
    • Tan, Carlyn Rose;
    • Derkach, Andriy;
    • Nemirovsky, David;
    • Ciardiello, Amanda;
    • Diamond, Benjamin;
    • Hultcrantz, Malin;
    • Hassoun, Hani;
    • Mailankody, Sham;
    • Shah, Urvi;
    • Maclachlan, Kylee;
    • Patel, Dhwani;
    • Lahoud, Oscar B.;
    • Landau, Heather J.;
    • Chung, David J.;
    • Shah, Gunjan L.;
    • Scordo, Michael;
    • Giralt, Sergio A.;
    • Lesokhin, Alexander;
    • Usmani, Saad Z.;
    • Landgren, Ola
    Publication type:
    Article
    9

    Extreme body mass index and survival in newly diagnosed multiple myeloma patients.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-022-00782-7
    By:
    • Shah, Urvi A.;
    • Whiting, Karissa;
    • Devlin, Sean;
    • Ershler, Rachel;
    • Kanapuru, Bindu;
    • Lee, David J.;
    • Tahri, Sabrin;
    • Gwise, Thomas;
    • Rustad, Even H.;
    • Mailankody, Sham;
    • Lesokhin, Alexander M.;
    • Kazandjian, Dickran;
    • Maura, Francesco;
    • Auclair, Daniel;
    • Birmann, Brenda M.;
    • Usmani, Saad Z.;
    • Gormley, Nicole;
    • Marinac, Catherine R.;
    • Landgren, Ola
    Publication type:
    Article
    10

    Nutrition perceptions, needs and practices among patients with plasma cell disorders.

    Published in:
    2022
    By:
    • Malik, Maria A.;
    • Sweeney, Nathan W.;
    • Jafri, Mohammad;
    • Derkach, Andriy;
    • Chmielewski, Cynthia;
    • Adintori, Peter A.;
    • Mailankody, Sham;
    • Korde, Neha;
    • Tan, Carlyn R.;
    • Hassoun, Hani;
    • Hultcrantz, Malin;
    • Hillengass, Jens;
    • McCann, Susan E.;
    • Iyengar, Neil;
    • Usmani, Saad;
    • Giralt, Sergio A.;
    • Landgren, Ola;
    • van den Brink, Marcel R. M.;
    • Ahlstrom, Jennifer M.;
    • Lesokhin, Alexander M.
    Publication type:
    Letter
    11

    Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma.

    Published in:
    Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-25469-8
    By:
    • Maclachlan, Kylee H.;
    • Rustad, Even H.;
    • Derkach, Andriy;
    • Zheng-Lin, Binbin;
    • Yellapantula, Venkata;
    • Diamond, Benjamin;
    • Hultcrantz, Malin;
    • Ziccheddu, Bachisio;
    • Boyle, Eileen M.;
    • Blaney, Patrick;
    • Bolli, Niccolò;
    • Zhang, Yanming;
    • Dogan, Ahmet;
    • Lesokhin, Alexander M.;
    • Morgan, Gareth J.;
    • Landgren, Ola;
    • Maura, Francesco
    Publication type:
    Article
    12

    Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.

    Published in:
    Leukemia & Lymphoma, 2012, v. 53, n. 2, p. 275, doi. 10.3109/10428194.2011.606943
    By:
    • Landau, Heather;
    • Pandit-Taskar, Neeta;
    • Hassoun, Hani;
    • Cohen, Adam;
    • Lesokhin, Alex;
    • Lendvai, Nikoletta;
    • Drullinsky, Pamela;
    • Schulman, Philip;
    • Jhanwar, Suresh;
    • Hoover, Elizabeth;
    • Bello, Christina;
    • Riedel, Elyn;
    • Nimer, Stephen D.;
    • Comenzo, Raymond L.
    Publication type:
    Article
    13
    14
    15
    16
    17

    S196: ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM‐3.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000967696.13096.54
    By:
    • Mohty, Mohamad;
    • Tomasson, Michael H.;
    • Arnulf, Bertrand;
    • Bahlis, Nizar J;
    • Rodríguez‐Otero, Paula;
    • Martinez‐Lopez, Joaquín;
    • Touzeau, Cyrille;
    • Quach, Hang;
    • Depaus, Julien;
    • Yokoyama, Hisayuki;
    • Manier, Salomon;
    • Raje, Noopur;
    • Raab, Marc S.;
    • Searle, Emma;
    • Leip, Eric;
    • Sullivan, Sharon T.;
    • Czibere, Akos;
    • Viqueira, Andrea;
    • Lesokhin, Alexander
    Publication type:
    Article
    18

    P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES.

    Published in:
    2023
    By:
    • Manier, Salomon;
    • Lesokhin, Alexander;
    • Mohty, Mohamad;
    • Niesvizky, Ruben;
    • Maisel, Christopher;
    • Arnulf, Bertrand;
    • Larson, Sarah M.;
    • Nina Varshavsky-Yanovsky, Asya;
    • Leleu, Xavier;
    • Karlin, Lionel;
    • Vesole, David H.;
    • Bahlis, Nizar J;
    • Fernandez de Larrea, Carlos;
    • Raje, Noopur;
    • Leip, Eric;
    • Sullivan, Sharon T.;
    • Elmeliegy, Mohamed;
    • Viqueira, Andrea;
    • Nooka, Ajay
    Publication type:
    Abstract
    19

    S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.

    Published in:
    2023
    By:
    • Munshi, Nikhil;
    • Martin, Tom;
    • Usmani, Saad Z;
    • Berdeja, Jesus;
    • Jakubowiak, Andrzej;
    • Agha, Mounzer;
    • Cohen, Adam D;
    • Deol, Abhinav;
    • Htut, Myo;
    • Lesokhin, Alexander;
    • Lin, Yi;
    • O'donnell, Elizabeth;
    • Jackson, Carolyn C;
    • Yeh, Tzu-Min;
    • Banerjee, Arnob;
    • Zudaire, Enrique;
    • Madduri, Deepu;
    • Delcorral, Christopher;
    • Pacaud, Lida;
    • Jagannath, Sundar
    Publication type:
    Abstract
    20

    P961: CILTACABTAGENE AUTOLEUCEL, A BCMA‐DIRECTED CAR‐T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2‐YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE‐1 STUDY.

    Published in:
    HemaSphere, 2022, v. 6, p. 851, doi. 10.1097/01.HS9.0000846712.74284.0f
    By:
    • Lin, Y.;
    • Martin, T.;
    • Berdeja, J. G.;
    • Jakubowiak, A.;
    • Agha, M.;
    • Cohen, A. D.;
    • Deol, A.;
    • Htut, M.;
    • Lesokhin, A.;
    • Munshi, N. C.;
    • O'Donnell, E.;
    • Jackson, C. C.;
    • Yeh, T.‐M.;
    • Banerjee, A.;
    • Zudaire, E.;
    • Madduri, D.;
    • Zhou, C.;
    • Pacaud, L.;
    • Usmani, S. Z.;
    • Jagannath, S.
    Publication type:
    Article
    21

    P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM‐3.

    Published in:
    HemaSphere, 2022, v. 6, p. 839, doi. 10.1097/01.HS9.0000846664.78859.dd
    By:
    • Lesokhin, A. M.;
    • Arnulf, B.;
    • Niesvizky, R.;
    • Mohty, M.;
    • Bahlis, N. J.;
    • Tomasson, M. H.;
    • Rodrίguez‐Otero, P.;
    • Quach, H.;
    • Raje, N. S.;
    • Iida, S.;
    • Raab, M.‐S.;
    • Czibere, A.;
    • Sullivan, S.;
    • Leip, E.;
    • Viqueira, A.;
    • Leleu, X.
    Publication type:
    Article
    22

    P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T‐CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA.

    Published in:
    HemaSphere, 2022, v. 6, p. 788, doi. 10.1097/01.HS9.0000846460.44039.3d
    By:
    • Dalovisio, A.;
    • Bahlis, N.;
    • Raje, N.;
    • Costello, C.;
    • Dholaria, B.;
    • Solh, M.;
    • Levy, M.;
    • Tomasson, M.;
    • Dube, H.;
    • Damore, M.;
    • Jiang, S.;
    • Basu, C.;
    • Skoura, A.;
    • Chan, E.;
    • Trudel, S.;
    • Jakubowiak, A.;
    • Chu, M.;
    • Gasparetto, C.;
    • Sebag, M.;
    • Lesokhin, A.
    Publication type:
    Article
    23
    24

    S177: EVALUATING SERUM FREE LIGHT CHAIN RATIO AS A BIOMARKER FOR MULTIPLE MYELOMA.

    Published in:
    HemaSphere, 2022, v. 6, p. 78, doi. 10.1097/01.HS9.0000843600.33023.0e
    By:
    • Akhlaghi, T.;
    • Maclachlan, K.;
    • Korde, N.;
    • Mailankody, S.;
    • Lesokhin, A.;
    • Hassoun, H.;
    • Lu, S. X.;
    • Patel, D.;
    • Shah, U.;
    • Tan, C.;
    • Derkach, A.;
    • Lahoud, O.;
    • Landau, H. J.;
    • Shah, G. L.;
    • Scordo, M.;
    • Chung, D. J.;
    • Giralt, S. A.;
    • Usmani, S. Z.;
    • Landgren, O.;
    • Hultcrantz, M.
    Publication type:
    Article
    25
    26
    27

    A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy.

    Published in:
    Leukemia & Lymphoma, 2022, v. 63, n. 14, p. 3488, doi. 10.1080/10428194.2022.2131417
    By:
    • Nath, Karthik;
    • Shekarkhand, Tala;
    • Salcedo, Meghan;
    • Derkach, Andriy;
    • Rueda, Siobhan;
    • Chansakul, Aisara;
    • Hulcrantz, Malin;
    • Korde, Neha;
    • Shah, Urvi A.;
    • Tan, Carlyn;
    • Chung, David J.;
    • Lahoud, Oscar B.;
    • Hassoun, Hani;
    • Lesokhin, Alexander M.;
    • Landau, Heather J.;
    • Shah, Gunjan;
    • Scordo, Michael;
    • Giralt, Sergio A.;
    • Usmani, Saad Z.;
    • Roshal, Mikhail
    Publication type:
    Article
    28
    29
    30

    Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach.

    Published in:
    Leukemia & Lymphoma, 2022, v. 63, n. 9, p. 2126, doi. 10.1080/10428194.2022.2062347
    By:
    • Lahoud, Oscar B.;
    • Landau, Heather;
    • Nguyen, James;
    • Devlin, Sean;
    • Lendvai, Nikoletta;
    • Weltz, Jonathan;
    • Ayorinde, Tumininu;
    • Chung, David J.;
    • Lesokhin, Alexander M.;
    • Kewalramani, Tarun;
    • Korde, Neha;
    • Mailankody, Sham;
    • Landgren, Ola;
    • Giralt, Sergio;
    • Comenzo, Raymond L.;
    • Hassoun, Hani
    Publication type:
    Article
    31
    32
    33
    34
    35

    Proteomic profiling in plasma cell disorders: a feasibility study.

    Published in:
    Leukemia & Lymphoma, 2017, v. 58, n. 7, p. 1757, doi. 10.1080/10428194.2016.1258699
    By:
    • Mailankody, Sham;
    • Devlin, Sean M.;
    • Korde, Neha;
    • Lendvai, Nikoletta;
    • Lesokhin, Alexander;
    • Landau, Heather;
    • Hassoun, Hani;
    • Ballagi, Andrea;
    • Ekman, Daniel;
    • Chung, David J.;
    • Patel, Minal;
    • Koehne, Guenther;
    • Giralt, Sergio;
    • Landgren, Ola
    Publication type:
    Article
    36

    Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency*.

    Published in:
    Leukemia & Lymphoma, 2017, v. 58, n. 5, p. 1123, doi. 10.1080/10428194.2016.1239261
    By:
    • Ogunniyi, Adebayo;
    • Rodriguez, Mabel;
    • Devlin, Sean;
    • Adel, Nelly;
    • Landau, Heather;
    • Chung, David J.;
    • Lendvai, Nikoletta;
    • Lesokhin, Alexander;
    • Koehne, Guenther;
    • Mailankody, Sham;
    • Korde, Neha;
    • Reich, Lilian;
    • Landgren, Ola;
    • Giralt, Sergio;
    • Hassoun, Hani
    Publication type:
    Article
    37
    38
    39
    40
    41
    42

    Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma.

    Published in:
    Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-40966-8
    By:
    • Coffey, David G.;
    • Maura, Francesco;
    • Gonzalez-Kozlova, Edgar;
    • Diaz-Mejia, J. Javier;
    • Luo, Ping;
    • Zhang, Yong;
    • Xu, Yuexin;
    • Warren, Edus H.;
    • Dawson, Travis;
    • Lee, Brian;
    • Xie, Hui;
    • Smith, Eric;
    • Ciardiello, Amanda;
    • Cho, Hearn J.;
    • Rahman, Adeeb;
    • Kim-Schulze, Seunghee;
    • Diamond, Benjamin;
    • Lesokhin, Alexander;
    • Kazandjian, Dickran;
    • Pugh, Trevor J.
    Publication type:
    Article
    43
    44

    Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 9, p. 10254, doi. 10.1002/cam4.5753
    By:
    • Lesokhin, Alexander;
    • LeBlanc, Richard;
    • Dimopoulos, Meletios A.;
    • Capra, Marcelo;
    • Carlo‐Stella, Carmelo;
    • Karlin, Lionel;
    • Castilloux, Jean‐Francois;
    • Forsberg, Peter;
    • Parmar, Gurdeep;
    • Tosikyan, Axel;
    • Pour, Ludek;
    • Ribrag, Vincent;
    • Ribolla, Rossella;
    • Abdallah, Al‐Ola;
    • Le Roux, Nadia;
    • Dong, Liyan;
    • van de Velde, Helgi;
    • Mayrargue, Laurent;
    • Lépine, Lucie;
    • Macé, Sandrine
    Publication type:
    Article
    45

    Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.

    Published in:
    British Journal of Haematology, 2022, v. 196, n. 1, p. 105, doi. 10.1111/bjh.17772
    By:
    • Piedra, Katrina;
    • Peterson, Tim;
    • Tan, Carlyn;
    • Orozco, Jennifer;
    • Hultcrantz, Malin;
    • Hassoun, Hani;
    • Mailankody, Sham;
    • Lesokhin, Alexander;
    • Shah, Urvi;
    • Lu, Sydney;
    • Patel, Dhwani;
    • Derkach, Andriy;
    • Wilkins, Cy R.;
    • Korde, Neha
    Publication type:
    Article
    46

    Comparison of MALDI‐TOF mass spectrometry analysis of peripheral blood and bone marrow‐based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.

    Published in:
    British Journal of Haematology, 2020, v. 189, n. 5, p. 904, doi. 10.1111/bjh.16443
    By:
    • Eveillard, Marion;
    • Rustad, Even;
    • Roshal, Mikhail;
    • Zhang, Yanming;
    • Ciardiello, Amanda;
    • Korde, Neha;
    • Hultcrantz, Malin;
    • Lu, Sydney;
    • Shah, Urvi;
    • Hassoun, Hani;
    • Smith, Eric;
    • Lesokhin, Alexander;
    • Mailankody, Sham;
    • Landgren, Ola;
    • Thoren, Katie
    Publication type:
    Article
    47

    Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.

    Published in:
    Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-22140-0
    By:
    • Oben, Bénedith;
    • Froyen, Guy;
    • Maclachlan, Kylee H.;
    • Leongamornlert, Daniel;
    • Abascal, Federico;
    • Zheng-Lin, Binbin;
    • Yellapantula, Venkata;
    • Derkach, Andriy;
    • Geerdens, Ellen;
    • Diamond, Benjamin T.;
    • Arijs, Ingrid;
    • Maes, Brigitte;
    • Vanhees, Kimberly;
    • Hultcrantz, Malin;
    • Manasanch, Elisabet E.;
    • Kazandjian, Dickran;
    • Lesokhin, Alexander;
    • Dogan, Ahmet;
    • Zhang, Yanming;
    • Mikulasova, Aneta
    Publication type:
    Article
    48
    49

    P-216: Daratumumab, Carfilzomib, Lenalidomide, & Dexamethasone for relapsed/refractory Myeloma with salvage autologous hematopoietic cell transplant: interim analysis of the multicenter 2nd chance protocol.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S158, doi. 10.1016/S2152-2650(21)02343-0
    By:
    • Gunjan Shah;
    • Bal, Susan;
    • Rodriguez, Cesar;
    • Chhabra, Saurabh;
    • Bayer, Ruthee;
    • Costa, Luciano;
    • Lambird, Jonathan;
    • Ferrer, Christine;
    • Parascondola, Allison;
    • Marcello, Leeann;
    • Shulman, Leah;
    • Obadi, Obadi;
    • Acosta, Jennifer;
    • Hassoun, Hani;
    • Hultcrantz, Malin;
    • Korde, Neha;
    • Mailankody, Sham;
    • Tan, Carlyn;
    • Shah, Urvi;
    • Lesokhin, Alexander
    Publication type:
    Article
    50

    P-152: Providing nutritional guidance for patients with plasma cell disorders – a missed opportunity for hematologists and oncologists?

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S118, doi. 10.1016/S2152-2650(21)02279-5
    By:
    • Sweeney, Nathan;
    • Malik, Maria;
    • Jafri, Mohammad;
    • Derkach, Andriy;
    • Chmielewski, Cynthia;
    • Adintori, Peter;
    • Mailankody, Sham;
    • Neha Korde;
    • Tan, Carlyn;
    • Hani Hassoun;
    • Hultcrantz, Malin;
    • Hillengass, Jens;
    • McCann, Susan;
    • Iyengar, Neil;
    • Giralt, Sergio;
    • Landgren, Ola;
    • van den Brink, Marcel;
    • Ahlstrom, Jenny;
    • Lesokhin, Alexander;
    • D'Souza, Anita
    Publication type:
    Article